Delirium, Dementia, Amnestic, Cognitive Disorders  >>  PF-05236812  >>  Phase 1
Welcome,         Profile    Billing    Logout  

2 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
PF-05236812 / J&J, Pfizer
NCT01193608: Study Evaluating The Safety Of AAB-003 (PF-05236812) In Subjects With Alzheimer's Disease

Completed
1
88
US, RoW
AAB-003 (PF-05236812), Placebo
Pfizer, JANSSEN Alzheimer Immunotherapy Research & Development, LLC
Alzheimer's Disease
10/13
10/13
NCT01369225: Open Label Extension Study Evaluating Safety and Tolerability of AAB-003 (PF-05236812) in Subject With Mild to Moderate Alzheimer's Disease

Completed
1
52
US, RoW
AAB-003 (PF-05236812)
Pfizer, JANSSEN Alzheimer Immunotherapy Research & Development, LLC
Alzheimer's Disease
08/14
08/14

Download Options